Special Issue

Ending Tuberculosis Epidemic: Current Status and Future Prospects

Message from the Guest Editor

Mycobacterium tuberculosis, a causative agent of tuberculosis (TB), causes millions of deaths around the world. Bacille Calmette-Guérin (BCG), an attenuated strain of *Mycobacterium bovis*, is currently the only approved vaccine for TB prevention, and has been since 1921. BCG confers protection to neonates against childhood TB as well as disseminated TB but does not protect against adult pulmonary TB. As we move forward, there is an acute need for the development of preventative or therapeutic vaccine strategies, adjunctive host-directed therapeutic (HDT) approaches and chemotherapeutics for TB treatment in order to end the global TB epidemic by 2035, to achieve the goals of the WHO End TB strategy. This Special Issue, on "Ending TB Epidemic: Current Status and Future Prospects", invites submissions on TB-preventive vaccines, therapeutic vaccines and strategies, adjunctive hostdirected therapies to control TB, chemotherapeutics to sterilize TB, Mtb virulence and pathogenesis, epidemiology, reported cases, clinical trials and policy research, as well as other relevant approaches.

Guest Editor

Dr. Sangeeta Tiwari

Department of Biological Sciences, University of Texas at El Paso, El Paso, TX 79968, USA

Deadline for manuscript submissions

closed (20 January 2023)



Tropical Medicine and Infectious Disease

an Open Access Journal by MDPI

Impact Factor 2.6 CiteScore 4.7 Indexed in PubMed



mdpi.com/si/128726

Tropical Medicine and Infectious Disease Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 tropicalmed@mdpi.com

mdpi.com/journal/ tropicalmed





Tropical Medicine and Infectious Disease

an Open Access Journal by MDPI

Impact Factor 2.6 CiteScore 4.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. John Frean

Pathologist, Parasitology Reference Laboratory, Centre for Emerging Zoonotic and Parasitic Diseases, National Institute for Communicable Diseases, University of the Witwatersrand, Johannesburg 2192, South Africa

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, Informit, and other databases.

Journal Rank:

JCR - Q1 (Tropical Medicine) / CiteScore - Q2 (Public Health, Environmental and Occupational Health)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 20.6 days after submission; acceptance to publication is undertaken in 3.1 days (median values for papers published in this journal in the first half of 2025).

